Compass Therapeutics (CMPX) Equity Ratio (2023 - 2025)
Compass Therapeutics' Equity Ratio history spans 3 years, with the latest figure at 0.9 for Q4 2025.
- For Q4 2025, Equity Ratio changed 0.47% year-over-year to 0.9; the TTM value through Dec 2025 reached 0.9, changed 0.47%, while the annual FY2025 figure was 0.9, 0.47% changed from the prior year.
- Equity Ratio for Q4 2025 was 0.9 at Compass Therapeutics, down from 0.91 in the prior quarter.
- Across five years, Equity Ratio topped out at 0.97 in Q1 2024 and bottomed at 0.8 in Q2 2025.
- The 3-year median for Equity Ratio is 0.93 (2023), against an average of 0.91.
- The largest annual shift saw Equity Ratio increased 4.54% in 2024 before it fell 14.93% in 2025.
- A 3-year view of Equity Ratio shows it stood at 0.95 in 2023, then dropped by 5.8% to 0.89 in 2024, then grew by 0.47% to 0.9 in 2025.
- Per Business Quant, the three most recent readings for CMPX's Equity Ratio are 0.9 (Q4 2025), 0.91 (Q3 2025), and 0.8 (Q2 2025).